Discrimination between Circulating Endothelial Cells and Blood Cell Populations with Overlapping Phenotype Reveals Distinct Regulation and Predictive Potential in Cancer Therapy  by Starlinger, Patrick et al.
Discrimination between
Circulating Endothelial Cells
and Blood Cell Populations with
Overlapping Phenotype Reveals
Distinct Regulation and Predictive
Potential in Cancer Therapy1
Patrick Starlinger, Philipp Brugger, Christian Reiter,
Dominic Schauer, Silvia Sommerfeldt,
Dietmar Tamandl, Irene Kuehrer,
Sebastian F. Schoppmann, Michael Gnant
and Christine Brostjan
Department of Surgery, Medical University of Vienna,
General Hospital, Vienna, Austria
Abstract
BACKGROUND: Circulating endothelial cells (CECs) have been proposed to predict patient response to antiangio-
genic cancer therapy. However, contradictory reports and inconsistency in the phenotypic identification of CECs
have led us to compare three cell populations with partially overlapping phenotype in cancer patients receiving
chemotherapy and the antiangiogenic agent bevacizumab. METHODS: Patients (n = 20) with locally advanced
pancreatic cancer were monitored during 16 weeks of neoadjuvant treatment with gemcitabine and bevacizumab.
Detection of circulating cell populations was based on the marker combination CD45, CD31, and CD146; levels of
viable and dead (7-aminoactinomycin D–positive) cells were evaluated by flow cytometry in 2-week intervals. RE-
SULTS:We were able to discriminate and concomitantly monitor three cell populations elevated in cancer patients.
Whereas CECs were defined as CD45− CD31+ CD146+, the distinct populations of CD45− CD31− CD146+ and
CD45− CD31high CD146− cells were partly positive for CD3 and CD41, respectively. CECs and CD45− CD31−
CD146+ cells increased during therapy; the rise in dead cells was positively correlated with patient response or
survival. Conversely, CD45− CD31high CD146− cells decreased in neoadjuvant treatment. A highly significant cor-
relation was established for improved patient response and a minor decrease in viable cell counts. CONCLUSIONS:
Flow cytometric CEC analysis based on CD45, CD31, and CD146 requires careful discrimination between blood
cell populations with overlapping phenotype showing hallmarks of activated T cells and large platelets. However,
these three cell populations show distinct regulation during cancer therapy, and their concomitant analysis may
offer extended prognostic and predictive information.
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Introduction
Antiangiogenic treatment has gained importance in cancer therapy
during the last decade [1]. Thus, bevacizumab, a neutralizing mono-
clonal antibody to proangiogenic vascular endothelial growth factor
(VEGF) has shown benefit as single agent or in combination with
standard chemotherapy in various types of cancer [2–4]. However,
a remarkable number of patients do not respond to VEGF-targeted
therapy [5,6]. Therefore, markers to identify patients most likely to
profit from antiangiogenic treatment are urgently needed [7,8].
Among the potential biomarkers that have been tested in the con-
text of anti-VEGF therapy, circulating endothelial cells (CECs) have
Abbreviations: 7-AAD, 7-aminoactinomycin D; CEC, circulating endothelial cell;
VEGF, vascular endothelial growth factor
Address all correspondence to: Prof. Christine Brostjan, Department of Surgery, Medical
University of Vienna, Vienna General Hospital, Anna Spiegel Research Building AKH
25.05.002, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
E-mail: christine.brostjan@meduniwien.ac.at
1This work was supported by the Austrian National Bank (OeNB grant no. 12072
issued to S.F. Schoppmann). The clinical study was sponsored by Roche Pharmaceu-
ticals, whereas the conducted biomarker analysis did not receive financial support by
the company.
Received 3 July 2011; Revised 28 August 2011; Accepted 6 September 2011
Copyright © 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00
DOI 10.1593/neo.11916
www.neoplasia.com
Volume 13 Number 10 October 2011 pp. 980–990 980
shown promising results [9]. Of note, a multitude of detection meth-
ods have been applied for CEC enumeration, which greatly limits
comparability. This is reflected by an enormous heterogeneity in
the reported blood levels of CECs and their ascribed potential to pre-
dict patient survival and therapy response [10–13].
Flow cytometric detection and immunomagnetic bead isolation of
CECs in whole blood samples are the most commonly applied CEC
quantitation methods in clinical studies. Whereas immunomagnetic
bead isolation is more readily standardized, analysis by flow cytome-
try offers the advantage to discriminate between cell populations with
distinct antigen expression levels and therefore yields more detailed
information on cell subsets and their predictive potential. In partic-
ular, the lack of an endothelial cell–specific marker and the antigen
overlap with other blood cells have raised major concerns that CEC
detection might include cells of nonendothelial origin. CEC identi-
fication was frequently based on the marker combinations CD45−
CD146+ CD31+ or CD45− CD146+ CD34+. It was subsequently
found that large platelets (CD45− CD146− CD31+ CD34+) and ac-
tivated T cells (CD45+ CD146+ CD31+ CD34−) share antigenic de-
terminants that may interfere with CEC evaluation [14–17]. This
has recently led to the development of advanced flow cytometry pro-
tocols including platelet discriminators such as DNA stains and re-
fined gating strategies to eliminate contaminating cell populations
and focus on CEC detection [18,19].
In 2006 to 2008, we conducted a clinical trial with locally ad-
vanced pancreatic cancer patients and monitored CEC blood levels
during neoadjuvant treatment with bevacizumab and gemcitabine.
CEC detection was based on the original flow cytometry protocol
(CD45− CD146+ CD31+) established by Mancuso et al. [20]. While
the procedure has meanwhile been revised [19], we found that the
original protocol offers the possibility to discriminate between three
cell populations of distinct phenotype which carry hallmarks of T cells,
large platelets, and CECs, respectively. We hypothesized that the
three cell populations show distinct regulation during therapy, and
we aimed to establish whether careful discrimination between these
subsets might improve the predictive and prognostic information of
CEC monitoring.
Materials and Methods
Study Collectives and Study Design
Twenty previously untreated patients with locally advanced, non-
metastatic pancreatic cancer (UICC stage III [T4, any N, M0]: tu-
mor has spread beyond the pancreas into nearby large blood vessels
[T4], there may be spread to regional lymph nodes [any N], but no
distant metastasis [M0]) were enrolled in the study. Exclusion criteria
comprised stage IA to IIB and stage IV disease, any prior systemic
cancer treatment, major surgery within the last 28 days, a history
of bleeding or coagulation disorders, as well as other malignant dis-
eases within the last 5 years.
Patients were randomly assigned to two treatment arms. Both
groups received 1000 mg/m2 gemcitabine on days 1, 8, and 15 of
four consecutive 4-week cycles. Group 1 (four women and five
men; median age = 65 years, range = 43-77 years) started with the
biweekly addition of 5 mg/kg bevacizumab in week 3 of the second
cycle. Patients in group 2 (five women and six men; median age =
62 years, range = 52-80 years) received bevacizumab from the begin-
ning of chemotherapy. The fourth cycle did not include bevacizumab,
providing a gap of at least 8 weeks between the last antibody dose and
pancreatic surgery. Blood samples for CEC and VEGF monitoring
were drawn from patients at 2-week intervals during the entire neo-
adjuvant treatment period. Levels of the tumor marker CA-19-9 were
determined by routine hospital analysis. Furthermore, one-time blood
samples were taken from a control collective of 30 healthy volunteers
comprising 11 women and 19 men, with a median age of 58 years,
ranging from 45 to 74 years.
The clinical study was registered in the public registry EudraCT
(no. 2005-004519-32). The study protocol and the analysis of blood
samples were approved by the institutional ethics committee; all pa-
tients and healthy volunteers gave written informed consent.
Assessment of VEGF Blood Concentrations
Platelet-poor plasma was prepared as previously reported by us
[21]. In brief, peripheral blood was drawn into prechilled tubes con-
taining citrate, theophylline, adenosine, and dipyridamole; was im-
mediately placed on ice; and further processed within 30 minutes.
After an initial centrifugation step at 1000g and 4°C for 10 minutes,
the plasma supernatant was subjected to further centrifugation at
10,000g and 4°C for 10 minutes (to remove remaining platelets).
Plasma samples were analyzed by a commercially available enzyme-
linked immunosorbent assay for VEGF-A (Quantikine; R&D Systems
[Minneapolis, MN] or Invitrogen Corp [Camarillo, CA]), which ex-
hibits the capacity to detect bevacizumab-bound VEGF-A with re-
duced sensitivity.
Immunostaining and Flow Cytometric Detection of CECs
Three milliliters of peripheral blood was drawn in EDTA tubes,
and 200 μl was subjected to immunostaining with anti-human
CD45−PC5 (Immunotech, Beckman Coulter, Brea, CA), CD31–
fluorescein isothiocyanate (Immunotech), CD146-phycoerythrin
(Chemicon, Billerica, MA), and 7-aminoactinomycin D (7-AAD;
Immunotech). Addition of CD3-PC7 (Immunotech) or CD41-
PC7 (Immunotech) was applied in a limited set of analyses. After
a “lyse-no-wash” procedure with VersaLyse reagent (Immunotech),
the samples were analyzed with an FC500 flow cytometer (Beckman
Coulter) for the detection of three cell populations: 1) CD45− CD31+
CD146+, 2) CD45− CD31− CD146+, and 3) CD45− CD31high
CD146−. To evaluate cell viability 7-AAD was applied. In total,
500,000 blood cells were analyzed by flow cytometry, and cell counts
of the three identified cell populations are given in relation to the
500,000 measured blood cells. Flow cytometric data were subsequently
processed with Kaluza Analysis 1.0 software (Beckman Coulter).
Evaluation of Response
Objective tumor response to neoadjuvant treatment was evaluated
by computed tomography or magnetic resonance imaging and was
defined in categories of progressive disease, stable disease, or partial
remission according to Response Evaluation Criteria in Solid Tumors
(RECIST). Overall survival of patients was assessed in a 2-year follow-
up period (with 1 patient alive at the time of study closure).
Statistical Analysis
Statistical analyses were carried out with SPSS 17.0.1 Software
(SPSS, Inc, Chicago, IL) and were based on nonparametric tests for
correlation (Spearman test, two-sided) and differences between treat-
ment groups (Mann-Whitney U test, two-sided) or time points of
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analysis (Wilcoxon test, two-sided). For the assessment of treatment-
related changes in parameter levels, regression analysis was performed
for all time points of blood sampling per patient. The slope (incline) k
as determined by regression analysis, as well as the baseline and end
point measurements of the three cell populations were separately eval-
uated for correlation with treatment response and patient survival
(Spearman test, two-sided). Data are generally presented by box plot
illustration; outliers and extreme values are not depicted.
Figure 1. Flow cytometric discrimination of blood cell populations based on CD45, CD31, and CD146 detection. Immunostaining of
peripheral blood with 7-AAD, fluorescein isothiocyanate–labeled anti-CD31, phycoerythrin-labeled anti-CD146, and PC5-labeled anti-
CD45 antibodies was followed by erythrolysis and flow cytometry. A total of 500,000 blood cells were evaluated in gate G1 of forward
and side scatter analysis (A) and were investigated for CD45 expression (B). The CD45-negative population was defined by gate G2.
Further assessment of CD31 and CD146 expression was based on G2 gating (in C and D). The detection of three distinct cell populations
with CD45− CD31+ CD146+, CD45− CD31− CD146+, and CD45− CD31high CD146− phenotype was compared for blood obtained from a
healthy individual (C) and a pancreatic cancer patient undergoing chemotherapy (D). Blood samples from five healthy subjects were
further stained with PC7-labeled anti-CD3 (E) or anti-CD41 (F) antibodies. The analyses are presented as gated on the CD45− CD31−
CD146+ cell subset (E) and the CD45− CD31high CD146− population (F), respectively.
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Results
Flow Cytometric Identification of Three Blood Cell
Populations with Distinct CD45, CD31, and
CD146 Phenotype
Peripheral blood cells were stained with antibodies directed to
CD45, CD31, and CD146. Cells were not discriminated based on
forward or side scatter properties but were gated according to CD45
detection (Figure 1, A and B). When CD45-negative cells were eval-
uated for surface expression of CD31 and CD146, three distinct cell
populations became apparent characterized by double-positive CD31+
CD146+ or single-positive CD31− CD146+ and CD31high CD146−
phenotypes. Furthermore, the proportion of viable (7-AAD–negative)
and dead (7-AAD–positive) cells was established for each cell type.
The prevalence of cell populations differed between healthy individuals
and tumor patients under therapy (Figure 1, C and D) and was subject
to subsequent investigation.
In addition, when antibodies to CD3 or CD41 were included in
the analysis to further characterize the three cell populations (Fig-
ure 1, E and F ), we found the CD45− CD31− CD146+ subset to
be largely positive for CD3, whereas the two other cell populations
were negative for CD3 expression. Comparably, the CD45− CD31high
CD146− cells presented partially positive for CD41. Thus, in contrast
to the proposed CEC population (CD45− CD31+ CD146+ cells), T-
cell characteristics (CD3) were found for the CD45− CD31− CD146+
subset, and hallmarks of platelets (CD41) were detected within the
CD45− CD31high CD146− population. It should be noted that
CD45− CD31high CD146− cells represented a distinctive subset of
the general platelet population that was detected by CD45− CD31low
CD146− marker expression (Figure 1, C and D).
Comparison of Pancreatic Cancer Patients and
Healthy Controls
The three defined cell populations were evaluated in 16 untreated
patients with locally advanced pancreatic cancer and 30 age-matched
healthy volunteers. Comparing the two collectives a 2.3-fold ele-
vation of median CD45− CD31+ CD146+ cell count was apparent
in cancer patients (P = .046) corresponding to 2 and 4.5 events in
500,000 blood cells in healthy subjects and patients, respectively.
When evaluated separately for viable and dead CD45− CD31+
CD146+ cells (Figure 2A), both fractions showed a broader distribu-
tion in cancer patients, with viable cell concentrations being signifi-
cantly higher in disease (P = .040).
Similarly, viable CD45− CD31− CD146+ cells were remarkably
elevated in cancer patients resulting in a 5.4-fold increase of total cell
count (Figure 2B; P < .001) from median levels of 11 to 60 CD45−
CD31− CD146+ cells per 500,000 blood cells. Dead CD45− CD31−
CD146+ cells did not differ significantly between groups.
In line with these results, CD45− CD31high CD146− cells were
found to be significantly (9.5-fold; P < .001) elevated in cancer pa-
tients. A median count of 24 per 500,000 blood cells was recorded
Figure 2. Comparison of blood cell populations in healthy individuals and pancreatic cancer patients. Blood levels of CD45− CD31+
CD146+ (A), CD45− CD31− CD146+ (B), and CD45− CD31high CD146− (C) cells were determined in 30 healthy volunteers and 16 pan-
creatic cancer patients before therapy. When applicable, viable and dead cell populations were discriminated based on 7-AAD staining.
The total platelet count was established for both groups (D). Data are illustrated by box plot; significant differences between cancer
patients and healthy volunteers are indicated.
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for tumor patients as opposed to 2.5 per 500,000 blood cells in
healthy volunteers (Figure 2C ). Of note, 7-AAD generally did not
stain CD45− CD31high CD146− cells, which may indicate a lack
of dead cells or a lack of nuclear DNA (being a hallmark of platelets).
Thus, we compared overall platelet counts in healthy individuals and
cancer patients but found no significant difference between groups
(Figure 2D).
Parameter Changes during Pancreatic Cancer Therapy
To investigate the time course of these blood cell populations in
cancer therapy, 20 patients with locally advanced pancreatic cancer
were randomized into two treatment arms (Figure 3A). Both study
groups received neoadjuvant gemcitabine therapy on days 1, 8, and
15 of four consecutive 4-week cycles. Group 2 received biweekly ad-
dition of bevacizumab from treatment start, whereas group 1 had a
delayed onset of bevacizumab therapy in week 3 of cycle 2. Blood
samples were collected at 2-week intervals during the neoadjuvant
treatment period to closely monitor therapy-induced changes in
blood cell populations. VEGF and CA-19-9 concentrations were de-
termined to further assess the therapeutic impact.
VEGF levels were found to increase rapidly on the first bevacizumab
administration (P = .002), which has previously been described as a
pharmacodynamic response to VEGF inactivation [22,23]. The rise
in VEGF plasma concentration was observed at time points 5 and 2
for treatment groups 1 and 2, respectively, corresponding to the dif-
ferential initiation of bevacizumab therapy in the treatment arms
(Figure 3, B and C). With respect to the tumor marker CA-19-9, a
significant decrease in blood concentration was evident (P = .006 for
starting and end point), but no significant difference between groups
was observed (Figure 3, D and E).
Figure 3. Blood levels of VEGF-A and CA-19-9 in pancreatic cancer patients undergoing neoadjuvant therapy. (A) Schematic represen-
tation of study design and blood sampling time points 1 to 8: The onset of bevacizumab administration is indicated by a dashed and
solid arrow for treatment groups 1 and 2, respectively. Plasma concentrations of VEGF (B, C) and CA-19-9 (D, E) according to blood
collection schedule are illustrated by box plot for all patients n = 20 (B, D) or for the individual treatment groups n1 = 9 and n2 = 11
(C, E). Please note that VEGF and CA-19-9 data have been presented in the context of another article relating to this study [34].
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In contrast to the tumor marker decline, a substantial increase in
viable CD45− CD31+ CD146+ cells was observed during pancreatic
cancer therapy (Figure 4) as evidenced by a positive correlation with
blood withdrawal time points (P = .003, k = 0.278). Of interest, cell
counts seemed to closely follow the chemotherapy schedule, as they
increased after chemotherapy administration and decreased after
therapy breaks. To more appropriately reflect these chemotherapy-
associated effects, cell measurements were assigned to two categories
based on gemcitabine administration: median values of viable CD45−
CD31+ CD146+ cells (Figure 4, A and B) established by blood sam-
pling 1 week after gemcitabine administration (time points 2, 4, 6,
and 8) ranged at 4.0 per 500,000 blood cells and were significantly
higher than cell counts recorded before therapy or after chemother-
apy breaks (time points 1, 3, 5, and 7), with a median value of
2.5 cells per 500,000 blood cells (P = .019). A comparable trend
was observed for dead CD45− CD31+ CD146+ cells (Figure 4, C
and D), as underlined by a significant correlation between dead and
viable cell counts (P < .001, k = 0.420). However, chemotherapy-
induced fluctuations were less pronounced for dead cells and did
not reach statistical significance. Correspondingly, viable but not
dead CD45− CD31+ CD146+ cells showed an inverse correlation with
the tumor marker CA-19-9 (P = .009, k = −0.251). No significant
difference in parameter fluctuations was observed between treatment
arms 1 and 2. However, when the analysis was limited to the first four
sampling points of chemotherapy without (group 1) or with (group 2)
bevacizumab supplementation, a significantly higher level of dead (P =
.005) but not of viable CD45− CD31+ CD146+ cells was recorded
after bevacizumab administration.
The impact of therapy on circulating CD45− CD31− CD146+ cells
was moderate and comparable between treatment groups (Figure 5).
Again, viable cell counts were significantly higher (P = .031) after che-
motherapy administration (median of 65 in 500,000 blood cells) than
after treatment breaks (median of 34 in 500,000 blood cells) and showed
a positive correlation with the fluctuations of viable CD45− CD31+
CD146+ cells (P = .002, k = 0.289). A similar trend for dead CD45−
CD31− CD146+ cells was illustrated in the correlation between dead
and viable CD45− CD31− CD146+ cell counts (P = .001, k = 0.308).
Remarkably, CD45− CD31high CD146− cells were inversely af-
fected by chemotherapy, that is, cells decreased after chemotherapy
administration and seemed to partially recover after chemotherapy
breaks (Figure 6, A and B). This pattern of regulation was reflected
in a significant difference (P = .017) of CD45− CD31high CD146−
cell counts for samples obtained after chemotherapy (median of
6 cells per 500,000 blood cells) as opposed to therapy breaks (median
of 11 cells per 500,000 blood cells). The general trend of CD45−
CD31high CD146− blood levels to decrease during neoadjuvant
treatment was reflected in a weak (inverse) correlation with sampling
time points (P = .049, k = −0.184). Overall, no differences relating to
treatment group were observed, and cells recorded were exclusively neg-
ative for 7-AAD. When comparing the overall fluctuations of platelet
Figure 4. Effects of neoadjuvant treatment on circulating CD45− CD31+ CD146+ cells in pancreatic cancer patients. The time course of
viable (A, B) and dead (C, D) cells is presented by box plot for the entire study collective n = 20 (A, C) or separately for treatment arms
n1 = 9 and n2 = 11 (B, D). Time points of blood withdrawal after gemcitabine administration are indicated by closed triangles placed
between plots.
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counts during therapy (Figure 6, C and D), a similar but more pro-
nounced “drop-and-rebound” pattern according to chemotherapy
schedule was evident (P < .001 for samples with or without preceding
gemcitabine administration).
Predictive and Prognostic Value of Blood Cell Populations
As we had monitored three distinct cell populations based on their
CD45, CD31, and CD146 phenotypes, it was of interest to further
compare their ability to predict therapy response (Figure 7) or overall
survival. Nineteen of 20 patients had died at the time of study clo-
sure (with a median survival time of 12 months irrespective of treat-
ment arm), and 16 patients were evaluated for therapy response
according to RECIST criteria. Whereas five patients had progressive
disease after neoadjuvant treatment, seven patients presented with
stable disease and four study participants showed partial regression.
Higher levels of total or dead cell counts for the CD45− CD31+
CD146+ population as recorded at the end of neoadjuvant chemo-
therapy were found to correlate with improved patient response
(Figure 7A; P = .047, k = 0.638). Correspondingly, the number of
dead cells but not the viable CD45− CD31+ CD146+ cell count after
therapy was associated with a longer survival time (Figure 7B; P =
.042, k = 0.594).
Comparably, the rise in dead but not in viable CD45− CD31−
CD146+ cells (as evaluated by the parameter incline during therapy)
showed a highly significant, positive correlation with therapy re-
sponse (Figure 7C ; P = .004, k = 0.681). Of note, the initial increase
within the first 2 weeks of therapy was also positively associated with
treatment response (P = .044, k = 0.615).
The most striking correlation with therapy response, however, was
observed for the CD45− CD31high CD146− cell population (Fig-
ure 7D). The parameter incline during therapy was positively associ-
ated with neoadjuvant treatment response (P = .001, k = 0.752), that
is, an enhanced patient response was reflected in a minor decrease of
circulating CD45− CD31high CD146− cells.
Discussion
The addition of bevacizumab to chemotherapy has shown benefit in
several neoplastic entities. Unfortunately, only a proportion of pa-
tients seem to profit from antiangiogenic treatment, and markers
to identify responders are urgently needed. CECs have shown prom-
ising results in this context. However, their enumeration is hampered
by the phenotypic overlap with other blood cell populations. On the
basis of an established flow cytometry protocol, we have been able
to discriminate and concomitantly monitor three cell subsets with
“CEC-like” phenotype. These cell populations showed differential
regulation in response to treatment and distinct predictive potential.
Our results may help to explain the heterogeneity in clinical CEC
reports and further indicate that the differential evaluation of these
cell populations offers improved predictive information.
Figure 5. Effects of neoadjuvant treatment on circulating CD45− CD31− CD146+ cells in pancreatic cancer patients. Viable (A, B) and
dead (C, D) cell counts as established for the indicated time points of blood withdrawal are presented by box plot for the entire study
collective n = 20 (A, C) or separately for treatment arms n1 = 9 and n2 = 11 (B, D). Sampling points after gemcitabine administration are
indicated by closed triangles placed between plots.
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With respect to the three blood cell populations with overlap-
ping phenotype, CECs were defined as CD45− CD31+ CD146+.
They are known to originate from destabilized vessels at tumor sites,
and CEC release is further aggravated by chemotherapy-induced ves-
sel injury. With the marker combination of CD45− CD31+ CD146+,
the inclusion of endothelial progenitor cells cannot be entirely ruled
out. However, based on the observation that endothelial progen-
itors may express low levels of CD45 and generally represent a small
fraction (<5%) of CD146+ CECs [24], the contribution of endo-
thelial progenitor cells to the established CEC counts is presum-
ably minor.
We further found a population of CD45− CD31− CD146+ cells to
largely carry the CD3 antigen, which is in accordance with previous
reports on CD146 expression by activated T cells [25]. They may
thus comprise a CD45-negative or CD45dim T-lymphocyte popula-
tion [26] not excluded by CD45 gating. This T-cell subset seems to
be activated in the tumor presence and to be further increased and
affected on tumor damage by cancer therapy. In addition, mesen-
chymal progenitors [27] have been characterized by the marker ex-
pression of CD45− CD31− CD146+ and may thus contribute to the
CD3− portion of this cell population.
In contrast, the CD45− CD31high CD146− cell subset presented
partly positive for the platelet marker CD41, was consistently nega-
tive for DNA staining by 7-AAD and generally followed the platelet
course during cancer therapy. As recently suggested by Strijbos et al.
[15], flow cytometric measurement of CD45− CD31high cells may
thus primarily detect a subset of large platelets which are a hallmark
of cancer-related thrombocytopenia. It should be noted, however,
that CD41 expression on CD45− CD31high CD146− cells was not
homogeneous, indicating that this cell population may vary in the
extent of CD41 expression or may comprise other cell types.
All three cell populations were found to be significantly elevated in
pancreatic cancer patients compared with healthy controls. The in-
crease was primarily based on viable (7-AAD–negative) cells, whereas
dead cell populations generally showed a similar tendency without
statistical significance. Levels of CECs were moderately elevated
(2.3-fold), whereas a pronounced increase was recorded for CD45−
CD31− CD146+ (5.4-fold) and CD45− CD31high CD146− cells
(9.5-fold), resulting in median concentrations of 4.5, 60, and 24 cells
per 500,000 investigated blood cells, respectively. When expressed in
cell counts per milliliter blood, median levels of 68, 805 and 344
were determined for CECs, CD45− CD31− CD146+ and CD45−
CD31high CD146− cells in pancreatic cancer patients. (The number
of detected CECs was low, and samples with zero events per 500,000
analyzed blood cells corresponding to 150 to 200 μl of whole blood
were occasionally recorded. Because these samples would be mis-
represented by deducing the number of CECs per ml blood, data
were generally given as determined for 500,000 investigated blood
cells.) In literature, CECs have repeatedly been described to be ele-
vated in tumor patients, and advanced detection protocols have re-
corded concentrations of 60 to 1800 predominantly viable CECs
per milliliter depending on tumor entity and progression [19]. The
Figure 6. Effects of neoadjuvant treatment on circulating CD45− CD31high CD146− cells and on general platelet counts in pancreatic
cancer patients. The time course of viable (7-AAD–negative) CD45− CD31high CD146− cells (A, B) and blood platelet counts (C, D) is
illustrated by box plot for the entire study collective n = 20 (A, C) or separately for treatment arms n1 = 9 and n2 = 11 (B, D). Time points
of blood withdrawal after gemcitabine administration are indicated by closed triangles placed between plots.
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comparably moderate, 2.3-fold elevated CEC level determined in our
study (68 cells per milliliter) may thus reflect the local stage of dis-
ease and is in agreement with a 2.7-fold CEC increase recently re-
ported for pancreatic cancer patients [28]. In contrast, CD45− CD31+
CD146− large platelets were proposed to reach substantially higher
blood concentrations [15], as reflected in our CD45− CD31high
CD146− cell count of 344 events per milliliter.
The determined pretreatment levels of the three cell populations
did not correlate with survival or response to therapy—a finding that
is supported by a number of other studies evaluating baseline CEC
values in cancer patients [10–12]. In contrast, significant correlations
of pretreatment CEC blood levels with patient prognosis and/or
therapy response were reported by others and may relate to the dif-
ference in type of cancer or CEC detection method applied [29–32].
Furthermore, we would like to note that the number of study par-
ticipants (n = 20) may be limiting for detecting small sample varia-
tions. However, the tight monitoring of parameter changes during
therapy (with eight sampling time points) has yielded a more com-
prehensive and conclusive evaluation of treatment related effects.
Thus, parameter regulation during therapy has been assessed based
on multiple measurements and by calculating the linear slope (in-
cline) in regression analysis.
With respect to treatment-related changes in the investigated param-
eters, we first evaluated blood levels of VEGF and CA-19-9. We
confirmed the previously documented increase in plasma VEGF on
bevacizumab administration [22,23] and a continuous decrease in
CA-19-9 levels throughout the neoadjuvant treatment. No significant
difference in tumor marker decline was observed between treatment
arms with three versus six doses of bevacizumab supplementation to
gemcitabine chemotherapy. Similarly, no substantial difference be-
tween treatment groups was apparent for the time course of the inves-
tigated blood cell populations.
CECs and CD45− CD31− CD146+ cells showed an overall in-
crease in response to the combination therapy, with coregulation
of viable and dead cell populations. However, the viable cell popula-
tions were more affected by a pronounced rebound (drop) phenom-
enon in chemotherapy breaks. In contrast, the number of dead CECs
was significantly higher on bevacizumab supplementation to gem-
citabine treatment. When evaluated for their predictive potential,
the therapy-induced increase in dead (rather than viable) CECs
and CD45− CD31− CD146+ cells showed a positive correlation with
patient benefit. Of particular interest, the immediate rise in dead
CD45− CD31− CD146+ cells within the first 2 weeks of therapy
was positively correlated with treatment response and warrants fur-
ther investigation as an early marker of response prediction.
A comparable and selective increase in dead (apoptotic) CECs has
previously been reported for responding breast cancer patients under
antiangiogenic, metronomic chemotherapy [11]. Similarly, a higher
increase in CECs was associated with a clinical benefit for patients
with gastrointestinal tumors receiving anti-VEGF receptor treat-
ment [33]. With respect to CD45− CD31− CD146+ cells, clinical
monitoring has not been actively pursued. However, Duda et al.
Figure 7. Association of blood cell populations with treatment response or survival. Posttherapy levels of total (dead and viable) CD45−
CD31+ CD146+ cells are presented by stacked bar plot according to treatment response (A). On the basis of the posttherapy levels of dead
CD45− CD31+ CD146+ cells, patients were divided into two groups with high (>10) versus low (≤10) CEC counts per 500,000 blood cells,
and the corresponding survival curves are plotted (B). The calculated parameter incline (k) during therapy is illustrated by box plot for dead
CD45− CD31− CD146+ (C) and viable CD45− CD31high CD146− cells (D) in relation to treatment response according to RECIST criteria.
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[17] reported a general increase of CD146+ CD3+ (CD45−/+) cells in
rectal cancer patients after bevacizumab administration.
The subset of CD45− CD31high CD146− cells showed an opposite
tendency to decrease during neoadjuvant treatment of pancreatic
cancer patients. Similar to the overall platelet count, a distinct drop
and rebound pattern was recorded for CD45− CD31high CD146−
cells in association with gemcitabine administration and chemo-
therapy breaks. However, the diagnostic and predictive potential of
CD45− CD31high CD146− cells was clearly distinct from the general
platelet population because overall platelet counts were not signifi-
cantly elevated in cancer patients and the therapy-related changes
were not associated with patient benefit. In contrast, an improved re-
sponse to treatment showed a highly significant correlation with a
minor decrease in CD45− CD31high CD146− cell concentrations dur-
ing therapy. A comparable population of CD45− CD31bright CD146−
cells has previously been reported to decrease after bevacizumab therapy
for rectal cancer patients [17], and cell levels after combined treatment
with bevacizumab and chemoradiotherapy were found to correlate with
patient response [13].
In conclusion, we have monitored three cell populations with over-
lapping phenotype based on a standard protocol for CEC detection by
flow cytometry. Whereas the distinct subsets have shown features of
CECs (CD45− CD31+ CD146+), T cells (CD45− CD31− CD146+),
and platelets (CD45− CD31high CD146−), their changes during can-
cer therapy rather than a comprehensive characterization of cell types
has been the focus of this investigation. We found them to be differen-
tially regulated by chemotherapy in combination with bevacizumab
and to exhibit distinct predictive potential. The diversity in literature
regarding CEC up- or down-regulation during cancer therapy and
the associated prognostic and predictive evidence might in part be
explained by a differential focus on or by the lack of discrimination be-
tween these cell populations. Thus, rather than distinguishing CECs
from cell populations with overlapping phenotype, such as platelets,
which have been effectively and successfully achieved by novel detec-
tion methods [19], the novelty of the described study is given in the
concomitant monitoring of CECs with two CEC-like cell populations
that have shown a distinct prognostic and predictive potential.
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